NorthRock Partners LLC Has $297,000 Holdings in Bruker Corporation $BRKR

NorthRock Partners LLC increased its stake in shares of Bruker Corporation (NASDAQ:BRKR) by 21.8% during the second quarter, HoldingsChannel.com reports. The fund owned 7,213 shares of the medical research company’s stock after purchasing an additional 1,291 shares during the period. NorthRock Partners LLC’s holdings in Bruker were worth $297,000 as of its most recent SEC filing.

Other hedge funds have also made changes to their positions in the company. Pinnacle Bancorp Inc. acquired a new position in shares of Bruker during the 1st quarter valued at about $29,000. Allworth Financial LP increased its holdings in shares of Bruker by 92.4% during the 1st quarter. Allworth Financial LP now owns 758 shares of the medical research company’s stock valued at $30,000 after acquiring an additional 364 shares during the last quarter. Caitong International Asset Management Co. Ltd increased its holdings in shares of Bruker by 1,354.5% during the 1st quarter. Caitong International Asset Management Co. Ltd now owns 800 shares of the medical research company’s stock valued at $33,000 after acquiring an additional 745 shares during the last quarter. Parallel Advisors LLC increased its holdings in shares of Bruker by 63.0% during the 2nd quarter. Parallel Advisors LLC now owns 898 shares of the medical research company’s stock valued at $37,000 after acquiring an additional 347 shares during the last quarter. Finally, Annis Gardner Whiting Capital Advisors LLC acquired a new position in shares of Bruker during the 1st quarter valued at about $42,000. Institutional investors and hedge funds own 79.52% of the company’s stock.

Insider Activity at Bruker

In related news, Director Cynthia M. Friend sold 3,535 shares of the firm’s stock in a transaction that occurred on Friday, September 12th. The stock was sold at an average price of $32.25, for a total transaction of $114,003.75. Following the completion of the transaction, the director owned 18,016 shares in the company, valued at $581,016. This trade represents a 16.40% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 27.30% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on BRKR. Stifel Nicolaus set a $40.00 price objective on Bruker and gave the company a “hold” rating in a report on Tuesday, August 5th. Bank of America decreased their target price on Bruker from $61.00 to $50.00 and set a “buy” rating for the company in a research note on Thursday, June 26th. Jefferies Financial Group set a $60.00 target price on Bruker and gave the company a “buy” rating in a research note on Monday, August 4th. Weiss Ratings restated a “sell (d+)” rating on shares of Bruker in a research note on Wednesday, October 8th. Finally, Wells Fargo & Company decreased their target price on Bruker from $60.00 to $50.00 and set an “overweight” rating for the company in a research note on Tuesday, August 5th. Five equities research analysts have rated the stock with a Buy rating, five have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $51.00.

Bruker Price Performance

Bruker stock opened at $38.20 on Friday. The company has a debt-to-equity ratio of 1.31, a current ratio of 1.61 and a quick ratio of 0.70. The company has a market capitalization of $5.80 billion, a PE ratio of 73.46, a price-to-earnings-growth ratio of 5.07 and a beta of 1.20. Bruker Corporation has a one year low of $28.53 and a one year high of $64.64. The business has a 50 day simple moving average of $33.35 and a 200 day simple moving average of $37.03.

Bruker (NASDAQ:BRKR) last posted its earnings results on Monday, August 4th. The medical research company reported $0.32 EPS for the quarter, missing the consensus estimate of $0.33 by ($0.01). The company had revenue of $797.40 million for the quarter, compared to the consensus estimate of $811.17 million. Bruker had a return on equity of 17.89% and a net margin of 2.31%.Bruker’s quarterly revenue was down .4% compared to the same quarter last year. During the same quarter last year, the business earned $0.52 EPS. Bruker has set its FY 2025 guidance at 1.950-2.050 EPS. On average, sell-side analysts forecast that Bruker Corporation will post 2.69 EPS for the current fiscal year.

Bruker Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Friday, October 3rd. Investors of record on Tuesday, September 23rd were given a dividend of $0.05 per share. This represents a $0.20 annualized dividend and a dividend yield of 0.5%. The ex-dividend date was Tuesday, September 23rd. Bruker’s dividend payout ratio (DPR) is 38.46%.

Bruker Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.